| Dr Keith G Gurland, MD | |
|
521 Broadway, Bayonne, NJ 07002-3735 | |
| (201) 339-1266 | |
| (201) 339-0122 |
| Full Name | Dr Keith G Gurland |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 47 Years |
| Location | 521 Broadway, Bayonne, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013098805 | NPI | - | NPPES |
| 180001825 | Other | NJ | RRMC |
| 2061201 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 03644300 (New Jersey) | Primary |
| Entity Name | Keith Gurland Md |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518496843 PECOS PAC ID: 2769757525 Enrollment ID: O20171004000501 |
News Archive
Zipnosis is getting the word out about an incredibly effective means of avoiding the spread of germs this cold and flu season: Use virtual care.
To keep reporters up to date with the latest developments on the age beat, The Gerontological Society of America (GSA) is proud to host a series of press briefings and a journalists' networking reception at its upcoming Annual Scientific Meeting in Atlanta, GA. The program schedule additionally offers over 400 other scientific sessions featuring research presented for the first time.
THE deliberations of a small group of specialists, meeting in Edinburgh tomorrow, will help make progress in cancer research all over the world.On Thursday (September 30) nineteen international scientists are due to get round the table to decide which cancer research projects, from the 125 in front of them, will benefit from a grants package totalling more than £4 million.
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Keith G Gurland, MD 521 Broadway, Bayonne, NJ 07002-3735 Ph: (201) 339-1266 | Dr Keith G Gurland, MD 521 Broadway, Bayonne, NJ 07002-3735 Ph: (201) 339-1266 |
News Archive
Zipnosis is getting the word out about an incredibly effective means of avoiding the spread of germs this cold and flu season: Use virtual care.
To keep reporters up to date with the latest developments on the age beat, The Gerontological Society of America (GSA) is proud to host a series of press briefings and a journalists' networking reception at its upcoming Annual Scientific Meeting in Atlanta, GA. The program schedule additionally offers over 400 other scientific sessions featuring research presented for the first time.
THE deliberations of a small group of specialists, meeting in Edinburgh tomorrow, will help make progress in cancer research all over the world.On Thursday (September 30) nineteen international scientists are due to get round the table to decide which cancer research projects, from the 125 in front of them, will benefit from a grants package totalling more than £4 million.
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.
› Verified 6 days ago